December 8, 2023 PAI Top-10

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2 Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2 These data will be presented as an oral presentation at the 2023 San Antonio... Read more

December 8, 2023 Uncategorized

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1 The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium... Read more

December 7, 2023 Microscopy Molecular Spectroscopy Product Launch

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers

Combining a Small Instrument Size with the Highest Levels of Sensitivity in Their Class, and Featuring a Model Suitable for High-Temperature/High-Humidity RegionsNew Compact IRSpirit-X Series Fourier Transform Infrared Spectrophotometers Read more

December 6, 2023 Lab Top-10

Danaher Completes Acquisition of Abcam

WASHINGTON, Dec. 6, 2023 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the “Scheme”) and the Scheme became effective... Read more

December 6, 2023 Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships Product Launch

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt Share of 127-megawatt aggregated deal in collaboration with Eurofins Scientific will power over half of Thermo Fisher’s addressable European footprint with 100% renewable electricity by 2025 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in... Read more

December 5, 2023 Bio/Pharma/CRO

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting... Read more